Resultats de la cerca - Jochen Utikal

Refinar resultats
  1. 1
    SOX2 and cancer: current research and its implications in the clinic

    SOX2 and cancer: current research and its implications in the clinic per Kasia Weina, Jochen Utikal

    Publicat 2014
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  2. 2
    Molecular genetics of Xeroderma pigmentosum variant

    Molecular genetics of Xeroderma pigmentosum variant per Alexei Gratchev, Pamela Strein, Jochen Utikal, Sergij Goerdt

    Publicat 2003
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  3. 3
    Interleukin‐4 and Dexamethasone Counterregulate Extracellular Matrix Remodelling and Phagocytosis in Type‐2 Macrophages

    Interleukin‐4 and Dexamethasone Counterregulate Extracellular Matrix Remodelling and Phagocytosis in Type‐2 Macrophages per Alexei Gratchev, Julia Kzhyshkowska, Jochen Utikal, Sergij Goerdt

    Publicat 2005
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells

    Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells per Jochen Utikal, Nimet Maherali, Warakorn Kulalert, Konrad Hochedlinger

    Publicat 2009
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression

    The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression per Viktor Umansky, C Blattner, Christoffer Gebhardt, Jochen Utikal

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  6. 6
    CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma

    CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma per Viktor Umansky, C Blattner, Christoffer Gebhardt, Jochen Utikal

    Publicat 2017
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  7. 7
    Extracellular adenosine metabolism in immune cells in melanoma

    Extracellular adenosine metabolism in immune cells in melanoma per Viktor Umansky, Ivan Shevchenko, Alexandr V. Bazhin, Jochen Utikal

    Publicat 2014
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  8. 8
    Reprogramming of Neural Progenitor Cells into Induced Pluripotent Stem Cells in the Absence of Exogenous Sox2 Expression

    Reprogramming of Neural Progenitor Cells into Induced Pluripotent Stem Cells in the Absence of Exogenous Sox2 Expression per Sarah Eminli, Jochen Utikal, Katrin Arnold, Rudolf Jaenisch, Konrad Hochedlinger

    Publicat 2008
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Leukocyte Count Restoration Under Dabrafenib Treatment in a Melanoma Patient With Vemurafenib-Induced Leukopenia

    Leukocyte Count Restoration Under Dabrafenib Treatment in a Melanoma Patient With Vemurafenib-Induced Leukopenia per Elias Orouji, Birgit Ziegler, Viktor Umansky, Christoffer Gebhardt, Jochen Utikal

    Publicat 2014
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    NRAS mutant melanoma: Towards better therapies

    NRAS mutant melanoma: Towards better therapies per Tijana Randic, Ines Kozar, Christiane Margue, Jochen Utikal, Stephanie Kreis

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  11. 11
    Induced Pluripotent Stem Cells Generated Without Viral Integration

    Induced Pluripotent Stem Cells Generated Without Viral Integration per Matthias Stadtfeld, Masaki Nagaya, Jochen Utikal, Gordon C. Weir, Konrad Hochedlinger

    Publicat 2008
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Oncogenic Role of an Epigenetic Reader of m6A RNA Modification: YTHDF1 in Merkel Cell Carcinoma

    Oncogenic Role of an Epigenetic Reader of m6A RNA Modification: YTHDF1 in Merkel Cell Carcinoma per Elias Orouji, Wiebke K. Peitsch, Azadeh Orouji, Roland Houben, Jochen Utikal

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target

    Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target per Feyza Gül Özbay Kurt, Samantha Lasser, Ihor Arkhypov, Jochen Utikal, Viktor Umansky

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  14. 14
    A High-Efficiency System for the Generation and Study of Human Induced Pluripotent Stem Cells

    A High-Efficiency System for the Generation and Study of Human Induced Pluripotent Stem Cells per Nimet Maherali, Tim Ahfeldt, Alessandra Rigamonti, Jochen Utikal, Chad A. Cowan, Konrad Hochedlinger

    Publicat 2008
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    SOX2 in development and cancer biology

    SOX2 in development and cancer biology per Daniel Novak, Laura Hüser, Jonathan J. Elton, Viktor Umansky, Peter Altevogt, Jochen Utikal

    Publicat 2019
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  16. 16
    Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression

    Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression per Christopher Groth, Xiaoying Hu, Rebekka Weber, Viktor Fleming, Peter Altevogt, Jochen Utikal, Viktor Umansky

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  17. 17
    Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma

    Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma per Vera Petrova, Ihor Arkhypov, Rebekka Weber, Christopher Groth, Peter Altevogt, Jochen Utikal, Viktor Umansky

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  18. 18
    Elevated chronic inflammatory factors and myeloid‐derived suppressor cells indicate poor prognosis in advanced melanoma patients

    Elevated chronic inflammatory factors and myeloid‐derived suppressor cells indicate poor prognosis in advanced melanoma patients per Huanhuan Jiang, Christoffer Gebhardt, Ludmila Umansky, Philipp Beckhove, Torsten J. Schulze, Jochen Utikal, Viktor Umansky

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression

    Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression per Viktor Fleming, Xiaoying Hu, Rebekka Weber, Vasyl S. Nagibin, Christopher Groth, Peter Altevogt, Jochen Utikal, Viktor Umansky

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  20. 20
    Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors

    Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors per Rebekka Weber, Viktor Fleming, Xiaoying Hu, Vasyl S. Nagibin, Christopher Groth, Peter Altevogt, Jochen Utikal, Viktor Umansky

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:

Eines de cerca: